Tibet Aim Pharm Inc
SZSE:002826
Tibet Aim Pharm Inc
SZSE:002826
Price:
20.83
CNY
3.58%
Market Closed
Market Cap:
¥4B
Relative Value
The Relative Value of one
Tibet Aim Pharm Inc
stock under the Base Case scenario is
11.71
CNY.
Compared to the current market price of 20.83 CNY,
Tibet Aim Pharm Inc
is
Overvalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
11.71
CNY
Overvaluation 44%
Multiples Across Competitors
Competitors Multiples
Tibet Aim Pharm Inc Competitors
Tibet Aim Pharm Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Tibet Aim Pharm Inc
SZSE:002826
|
4B CNY | 6.3 | 46.3 | 36 | 36 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
958.2B USD | 14.8 | 46.6 | 31.4 | 33.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
587.6B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
290.7B CHF | 4.7 | 30.9 | 13 | 15.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
246B CHF | 5.6 | 22.6 | 14 | 18 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.2B GBP | 5.4 | 30.8 | 17.1 | 24 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.8B USD | 4.6 | 16.4 | 10.2 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.4B USD | 2.6 | 17.5 | 7.3 | 9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
